Full history for every metric is available with a Kvantra account
Stock profile
Taiwan Liposome Company, Ltd. (TLC)
Current price
7.00 USD0.00%
Last close 28 Sep 2021Benchmarks
Key financial summary
Financials in TWD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | TWD m | 60 | 42 | 50 | 62 | 209 | 102 | 276 |
| Operating profit | TWD m | -983 | -822 | |||||
| Net profit | TWD m | -676 | -824 | -874 | -902 | -808 | -983 | -803 |
| EPS reported | TWD | -24.89 | -19.09 | |||||
| Operating cashflow per share | TWD | -22.15 | -22.15 | |||||
| Capex per share | TWD | 0.87 | 0.87 | |||||
| FCF per share | TWD | -23.02 | -23.02 | |||||
| Free cash flow | TWD m | -910 | -574 | |||||
| Net debt | TWD m | -675 | -697 | |||||
| Book value equity | TWD m | 438 | 151 | |||||
| Book value per share | TWD | 11.08 | 3.59 | |||||
| Number of shares | m | 39.51 | 42.08 | |||||
| DPS (TTM paid) | TWD | 0.00 | 0.00 |
Financial summary
Financials in TWD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 11.17 | 20.10 | |||||
| P/S LTM | x | 47.99 | 0.00 | |||||
| P/FCF LTM | x | -5.38 | 0.00 | |||||
| EV/EBITDA LTM | x | -4.64 | 0.74 | |||||
| EV/Sales LTM | x | 41.37 | -6.63 | |||||
| Earnings Yield LTM | % | -20.10% | -11.17% | |||||
| FCF Yield | % | -18.59% | - | |||||
| Quality | ||||||||
| ROE | % | -224.54% | -169.56% | |||||
| ROIC | % | -63.12% | -63.12% | |||||
| Operating margin | % | -964.51% | -964.51% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -892.36% | -892.36% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -51.26% | +406.06% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.36 | - | |||||
| Net Debt/EBITDA | x | 0.74 | 0.74 | |||||
| EBIT/Net interest | x | -60.12 | -60.12 | |||||
| Net debt/market cap | % | -13.80% | - | |||||
| Net debt/Equity | x | -1.54 | -4.62 | |||||
| Gross debt/equity | x | 1.52 | 0.00 | |||||
Company overview
No description available.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
TL
Taiwan Liposome Company, Ltd. (TLC)
TLC · NASDAQ · Healthcare
7.00 USD0.00%
Benchmarks
Financialsin TWD
20192020TTM
Total revenue TWD m209102276
Operating profit TWD m-983-822
Net profit TWD m-808-983-803
EPS reported TWD-24.89-19.09
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free